J. Schlessinger, Cell signaling by receptor tyrosine kinases, Cell, vol.103, pp.211-225, 2000.

A. H. Brivanlou, J. E. Darnell, and . Jr, Signal transduction and the control of gene expression, Science, vol.295, pp.813-818, 2002.

P. Blume-jensen and T. Hunter, Oncogenic kinase signalling, Nature, vol.411, pp.355-365, 2001.

A. Ullrich and J. Schlessinger, Signal transduction by receptors with tyrosine kinase activity, Cell, vol.61, pp.203-212, 1990.

Q. Pan, O. Shai, L. J. Lee, B. J. Frey, and B. J. Blencowe, Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing, Nat. Genet, vol.40, pp.1413-1415, 2008.

M. Sultan, M. H. Schulz, H. Richard, A. Magen, A. Klingenhoff et al., A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome, Science, vol.321, pp.956-960, 2008.

C. J. David and J. L. Manley, Alternative pre-mRNA splicing regulation in cancer: Pathways and programs unhinged, Genes Dev, vol.24, pp.2343-2364, 2010.

G. Chen, J. Wang, Z. Liu, and M. Kornmann, Exon III splicing of fibroblast growth factor receptor 1 is modulated by growth factors and cyclin D1, Pancreas, vol.37, pp.159-164, 2008.

D. Figueiredo-pontes, L. L. Wong, D. W. Tin, V. P. Chung, L. P. Yasuda et al., Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer, J. Thorac. Oncol, vol.9, pp.248-253, 2014.

J. P. O'bryan, R. A. Frye, P. C. Cogswell, A. Neubauer, B. Kitch et al., AXL, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase, Mol. Cell. Biol, vol.11, pp.5016-5031, 1991.

W. Vogel, G. D. Gish, F. Alves, and T. Pawson, The discoidin domain receptor tyrosine kinases are activated by collagen, Mol. Cell, vol.1, pp.13-23, 1997.

A. Guillaudeau, K. Durand, B. Bessette, A. Chaunavel, I. Pommepuy et al., EGFR soluble isoforms and their transcripts are expressed in meningiomas, PLoS ONE, vol.7, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00872638

H. K. Gan, A. N. Cvrljevic, and T. G. Johns, The epidermal growth factor receptor variant III (EGFRvIII): Where wild things are altered, FEBS J, vol.280, pp.5350-5370, 2013.

E. Padfield, H. P. Ellis, and K. M. Kurian, Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma. Front, Oncol, vol.5, 2015.

E. C. Piccione, T. J. Lieu, C. F. Gentile, T. R. Williams, A. J. Connolly et al., A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumors, Oncogene, vol.31, pp.2953-2967, 2012.

M. Sundvall, A. Korhonen, I. Paatero, E. Gaudio, G. Melino et al., Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms, Proc. Natl. Acad. Sci, vol.105, pp.4162-4167, 2008.

P. Zhang, J. S. Greendorfer, J. Jiao, S. C. Kelpke, and J. A. Thompson, Alternatively spliced FGFR-1 isoforms differentially modulate endothelial cell activation of c-YES, Arch. Biochem. Biophys, vol.450, pp.50-62, 2006.

V. P. Eswarakumar, I. Lax, and J. Schlessinger, Cellular signaling by fibroblast growth factor receptors, Cytokine Growth Factor Rev, vol.16, pp.139-149, 2005.

P. Malakar, L. Chartarifsky, A. Hija, G. Leibowitz, B. Glaser et al., Insulin receptor alternative splicing is regulated by insulin signaling and modulates ? cell survival, Sci. Rep, vol.6, p.31222, 2016.

G. M. Frampton, S. M. Ali, M. Rosenzweig, J. Chmielecki, X. Lu et al., Activation of met via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to met inhibitors, Cancer Discov, vol.5, pp.850-859, 2015.

D. Zheng, R. Wang, T. Ye, S. Yu, H. Hu et al., MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer, Oncotarget, vol.7, pp.41691-41702, 2016.

D. S. Richardson, D. M. Rodrigues, B. D. Hyndman, M. J. Crupi, A. C. Nicolescu et al., Alternative splicing results in RET isoforms with distinct trafficking properties, Mol. Biol. Cell, vol.23, pp.3838-3850, 2012.

C. Ghigna, M. De-toledo, S. Bonomi, C. Valacca, S. Gallo et al., Pro-metastatic splicing of ron proto-oncogene mrna can be reversed: Therapeutic potential of bifunctional oligonucleotides and indole derivatives, RNA Biol, vol.7, pp.495-503, 2010.
URL : https://hal.archives-ouvertes.fr/hal-02193461

S. Krishnaswamy, A. K. Mohammed, O. E. Amer, G. Tripathi, M. S. Alokail et al., Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15-19 in lung cancer, Lung Cancer, vol.92, pp.41-46, 2016.

A. Vaishnavi, A. T. Le, and R. C. Doebele, TRKing down an old oncogene in a new era of targeted therapy, Cancer Discov, vol.5, pp.25-34, 2015.

R. L. Kendall, G. Wang, and K. A. Thomas, Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR, Biochem. Biophys. Res. Commun, vol.226, pp.324-328, 1996.

S. Vorlova, G. Rocco, C. V. Lefave, F. M. Jodelka, K. Hess et al., Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation, Mol. Cell, vol.43, pp.927-939, 2011.

J. A. Meyerhardt, M. Ancukiewicz, T. A. Abrams, D. Schrag, P. C. Enzinger et al., Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer, PLoS ONE, vol.7, 2012.

R. S. Heist, D. G. Duda, D. V. Sahani, M. Ancukiewicz, P. Fidias et al., Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer, Proc. Natl. Acad. Sci, vol.112, pp.1547-1552, 2015.

X. Zhang, O. A. Ibrahimi, S. K. Olsen, H. Umemori, M. Mohammadi et al., Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family, J. Biol. Chem, vol.281, pp.15694-15700, 2006.

G. Yan, Y. Fukabori, G. Mcbride, S. Nikolaropolous, and W. L. Mckeehan, Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy, Mol. Cell. Biol, vol.13, pp.4513-4522, 1993.

J. Y. Cha, Q. T. Lambert, G. W. Reuther, and C. J. Der, Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis, Mol. Cancer Res, vol.6, pp.435-445, 2008.

Y. Q. Zhou, C. He, Y. Q. Chen, D. Wang, and M. H. Wang, Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: Generation of different splicing RON variants and their oncogenic potential, Oncogene, vol.22, pp.186-197, 2003.

D. Mitra, M. J. Brumlik, S. U. Okamgba, Y. Zhu, T. T. Duplessis et al., An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance, Mol. Cancer Ther, vol.8, pp.2152-2162, 2009.

R. N. Jorissen, F. Walker, N. Pouliot, T. P. Garrett, C. W. Ward et al., Epidermal growth factor receptor: Mechanisms of activation and signalling, Exp. Cell Res, vol.284, pp.31-53, 2003.

K. M. Ferguson, Structure-based view of epidermal growth factor receptor regulation, Annu. Rev. Biophys, vol.37, pp.353-373, 2008.

M. Perez-torres, B. L. Valle, N. J. Maihle, L. Negron-vega, R. Nieves-alicea et al., Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells, Exp. Cell Res, vol.314, pp.2907-2918, 2008.

M. P. Sanderson, S. Keller, A. Alonso, S. Riedle, P. J. Dempsey et al., Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion, J. Cell. Biochem, vol.103, pp.1783-1797, 2008.

J. L. Reiter and N. J. Maihle, A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor, Nucleic Acids Res, vol.24, pp.4050-4056, 1996.
URL : https://hal.archives-ouvertes.fr/in2p3-00024414

J. L. Reiter, D. W. Threadgill, G. D. Eley, K. E. Strunk, A. J. Danielsen et al., Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms, Genomics, vol.71, pp.1-20, 2001.

T. W. Flickinger, N. J. Maihle, and H. J. Kung, An alternatively processed mRNA from the avian c-erbB gene encodes a soluble, truncated form of the receptor that can block ligand-dependent transformation, Mol. Cell. Biol, vol.12, pp.883-893, 1992.

A. T. Baron, E. M. Cora, J. M. Lafky, C. H. Boardman, M. C. Buenafe et al., Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer, Cancer Epidemiol. Biomark. Prev, vol.12, pp.103-113, 2003.

K. S. Asgeirsson, A. Agrawal, C. Allen, A. Hitch, I. O. Ellis et al., Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients, Breast Cancer Res, vol.9, 2007.

S. Maramotti, M. Paci, G. Manzotti, C. Rapicetta, M. Gugnoni et al., Soluble epidermal growth factor receptors (sEGFRS) in cancer: Biological aspects and clinical relevance, Int. J. Mol. Sci, 2016.

Y. Lemos-gonzalez, F. J. Rodriguez-berrocal, O. J. Cordero, C. Gomez, and M. P. De-la-cadena, Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma, Br. J. Cancer, vol.96, pp.1569-1578, 2007.

J. H. Choi, J. Y. Oh, S. K. Ryu, S. J. Kim, N. Y. Lee et al., Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients, vol.79, pp.1879-1883, 1997.

E. Jantus-lewintre, R. Sirera, A. Cabrera, A. Blasco, C. Caballero et al., Analysis of the prognostic value of soluble epidermal growth factor receptor plasma concentration in advanced non-small-cell lung cancer patients, Clin. Lung Cancer, vol.12, pp.320-327, 2011.

F. Lococo, M. Paci, C. Rapicetta, T. Rossi, V. Sancisi et al., Preliminary evidence on the diagnostic and molecular role of circulating soluble EGFR in non-small cell lung cancer, Int. J. Mol. Sci, vol.16, 2015.

M. G. Zampino, E. Magni, L. Santoro, L. Zorzino, P. Dell'orto et al., Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?, Cancer Chemother. Pharmacol, vol.63, pp.139-148, 2008.

V. Muller, I. Witzel, K. Pantel, S. Krenkel, H. J. Luck et al., Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer, Anticancer Res, vol.26, pp.1479-1487, 2006.

P. H. Huang, A. M. Xu, and F. M. White, Oncogenic EGFR signaling networks in glioma, Sci. Signal, 2009.

M. Nagane, F. Coufal, H. Lin, O. Bogler, W. K. Cavenee et al., A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis, Cancer Res, vol.56, pp.5079-5086, 1996.

A. J. Ekstrand, C. D. James, W. K. Cavenee, B. Seliger, R. F. Pettersson et al., Genes for epidermal growth factor receptor, transforming growth factor ?, and epidermal growth factor and their expression in human gliomas in vivo, Cancer Res, vol.51, pp.2164-2172, 1991.

D. K. Moscatello, M. Holgado-madruga, A. K. Godwin, G. Ramirez, G. Gunn et al., Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors, Cancer Res, vol.55, pp.5536-5539, 1995.

M. M. Feldkamp, P. Lala, N. Lau, L. Roncari, and A. Guha, Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens, Neurosurgery, vol.45, pp.1442-1453, 1999.

Y. Nieto, F. Nawaz, R. B. Jones, E. J. Shpall, and S. Nawaz, Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer, J. Clin. Oncol, vol.25, pp.4405-4413, 2007.

H. Ge, X. Gong, and C. K. Tang, Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis, Int. J. Cancer, vol.98, pp.357-361, 2002.

V. Pillay, L. Allaf, A. L. Wilding, J. F. Donoghue, N. W. Court et al., The plasticity of oncogene addiction: Implications for targeted therapies directed to receptor tyrosine kinases, Neoplasia, vol.11, pp.448-458, 2009.

D. R. Emlet, P. Gupta, M. Holgado-madruga, C. A. Del-vecchio, S. S. Mitra et al., Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III, Cancer Res, vol.74, pp.1238-1249, 2014.

M. E. Halatsch, E. E. Gehrke, V. I. Vougioukas, I. C. Botefur, F. ;-a-borhani et al., Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines, J. Neurosurg, vol.100, pp.523-533, 2004.

H. K. Gan, A. H. Kaye, and R. B. Luwor, The EGFRvIII variant in glioblastoma multiforme, J. Clin. Neurosci, vol.16, pp.748-754, 2009.

J. L. Eller, S. L. Longo, D. J. Hicklin, and G. W. Canute, Activity of anti-epidermal growth factor receptor monoclonal antibody c225 against glioblastoma multiforme, Neurosurgery, vol.51, pp.1005-1014, 2002.

L. Li, T. S. Quang, E. J. Gracely, J. H. Kim, J. G. Emrich et al., A phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme, J. Neurosurg, vol.113, pp.192-198, 2010.

C. S. Kang, Z. Y. Zhang, Z. F. Jia, G. X. Wang, M. Z. Qiu et al., Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo, Cancer Gene Ther, vol.13, pp.530-538, 2006.

D. K. Moscatello, G. Ramirez, and A. J. Wong, A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors, Cancer Res, vol.57, pp.1419-1424, 1997.

J. H. Sampson, K. D. Aldape, G. E. Archer, A. Coan, A. Desjardins et al., Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma, Neuro Oncol, vol.13, pp.324-333, 2011.

A. J. Ekstrand, N. Sugawa, C. D. James, and V. P. Collins, Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails, Proc. Natl. Acad. Sci, vol.89, pp.4309-4313, 1992.

G. Pines, P. H. Huang, Y. Zwang, F. M. White, and Y. Yarden, EGFRvIV: A previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism, Oncogene, vol.29, pp.5850-5860, 2010.

M. Zhou, H. Wang, K. Zhou, X. Luo, X. Pan et al., A novel EGFR isoform confers increased invasiveness to cancer cells, Cancer Res, vol.73, pp.7056-7067, 2013.

F. Song, M. Zhou, B. Wang, B. Shi, H. Jiang et al., Weak binding to E3 ubiquitin ligase c-Cbl increases EGFRvA protein stability, FEBS Lett, vol.590, pp.1345-1353, 2016.

A. Eichmann and M. Simons, VEGF signaling inside vascular endothelial cells and beyond, Curr. Opin. Cell Biol, vol.24, pp.188-193, 2012.

T. Arcondeguy, E. Lacazette, S. Millevoi, H. Prats, and C. Touriol, VEGF-A mRNA processing, stability and translation: A paradigm for intricate regulation of gene expression at the post-transcriptional level, Nucleic Acids Res, vol.41, pp.7997-8010, 2013.

S. Oltean and D. O. Bates, Hallmarks of alternative splicing in cancer, Oncogene, vol.33, pp.5311-5318, 2014.

N. Ferrara, Vascular endothelial growth factor: Basic science and clinical progress, Endocr. Rev, vol.25, pp.581-611, 2004.

R. Roskoski and . Jr, Vascular endothelial growth factor (VEGF) signaling in tumor progression, Crit. Rev. Oncol. Hematol, vol.62, pp.179-213, 2007.

D. O. Bates, T. G. Cui, J. M. Doughty, M. Winkler, M. Sugiono et al., VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma, Cancer Res, vol.62, pp.4123-4131, 2002.

C. Suarez, S. Pieren, M. Cariolato, L. Arn, S. Hoffmann et al., Ballmer-Hofer, K. A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2, Cell. Mol. Life Sci, vol.63, pp.2067-2077, 2006.

H. Kawamura, X. Li, S. J. Harper, D. O. Bates, and L. Claesson-welsh, Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity, Cancer Res, vol.68, pp.4683-4692, 2008.

R. J. Albuquerque, T. Hayashi, W. G. Cho, M. E. Kleinman, S. Dridi et al., Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth, Nat. Med, vol.15, pp.1023-1030, 2009.

C. P. Thomas, J. I. Andrews, N. S. Raikwar, E. A. Kelley, F. Herse et al., A recently evolved novel trophoblast-enriched secreted form of fms-like tyrosine kinase-1 variant is up-regulated in hypoxia and preeclampsia, J. Clin. Endocrinol. Metab, vol.94, pp.2524-2530, 2009.

M. Heydarian, T. Mccaffrey, L. Florea, Z. Yang, M. M. Ross et al., Novel splice variants of sFlt1 are upregulated in preeclampsia, Placenta, vol.30, pp.250-255, 2009.

G. Szalai, R. Romero, T. Chaiworapongsa, Y. Xu, B. Wang et al., Full-length human placental sFlt-1-e15a isoform induces distinct maternal phenotypes of preeclampsia in mice, PLoS ONE, vol.10, p.119547, 2015.

C. Hornig, B. Barleon, S. Ahmad, P. Vuorela, A. Ahmed et al., Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids, Lab. Investig, vol.80, pp.443-454, 2000.

J. Jebbink, R. Keijser, G. Veenboer, J. Van-der-post, C. Ris-stalpers et al., Expression of placental FLT1 transcript variants relates to both gestational hypertensive disease and fetal growth, Hypertension, vol.58, pp.70-76, 2011.

S. A. Karumanchi and Y. Bdolah, Hypoxia and sFlt-1 in preeclampsia: The "chicken-and-egg" question, Endocrinology, vol.145, pp.4835-4837, 2004.

S. Sela, A. Itin, S. Natanson-yaron, C. Greenfield, D. Goldman-wohl et al., A novel human-specific soluble vascular endothelial growth factor receptor 1: Cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia, Circ. Res, vol.102, pp.1566-1574, 2008.

N. H. Kim, J. H. Oh, J. A. Seo, K. W. Lee, S. G. Kim et al., Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy, Kidney Int, vol.67, pp.167-177, 2005.

T. Yamaguchi, H. Bando, T. Mori, K. Takahashi, H. Matsumoto et al., Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis, Cancer Sci, vol.98, pp.405-410, 2007.

S. Ahmad and A. Ahmed, Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia, Circ. Res, vol.95, pp.884-891, 2004.

S. Ahmad, P. W. Hewett, B. Al-ani, S. Sissaoui, T. Fujisawa et al., Autocrine activity of soluble FLT-1 controls endothelial cell function and angiogenesis, Vasc. Cell, 2011.

L. Xia, Z. Dong, Y. Zhang, X. Zhang, X. Song et al., Interleukin-4 and granulocyte-macrophage colony-stimulating factor mediates the upregulation of soluble vascular endothelial growth factor receptor-1 in RAW264.7 cells-a process in which p38 mitogen-activated protein kinase signaling has an important role, J. Microbiol. Immunol. Infect, vol.49, pp.344-351, 2016.

Y. Xiong, D. A. Liebermann, J. S. Tront, E. J. Holtzman, Y. Huang et al., Geifman-Holtzman, O. Gadd45a stress signaling regulates sFlt-1 expression in preeclampsia, J. Cell. Physiol, vol.220, pp.632-639, 2009.

L. Anton, A. O. Olarerin-george, J. B. Hogenesch, and M. A. Elovitz, Placental expression of miR-517a/b and miR-517c contributes to trophoblast dysfunction and preeclampsia, PLoS ONE, vol.10, 2015.

J. N. Boeckel, V. Guarani, M. Koyanagi, T. Roexe, A. Lengeling et al., Jumonji domain-containing protein 6 (Jmjd6) is required for angiogenic sprouting and regulates splicing of VEGF-receptor 1, Proc. Natl. Acad. Sci, vol.108, pp.3276-3281, 2011.

T. Kangsamaksin, A. Murtomaki, N. M. Kofler, H. Cuervo, R. A. Chaudhri et al., NOTCH decoys that selectively block DLL/NOTCH or JAG/NOTCH disrupt angiogenesis by unique mechanisms to inhibit tumor growth, Cancer Discov, vol.5, pp.182-197, 2015.

R. L. Kendall and K. A. Thomas, Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor, Proc. Natl. Acad. Sci, vol.90, pp.10705-10709, 1993.

F. T. Wu, M. O. Stefanini, F. Mac-gabhann, C. D. Kontos, B. H. Annex et al., A systems biology perspective on sVEGFR1: Its biological function, pathogenic role and therapeutic use, J. Cell. Mol. Med, vol.14, pp.528-552, 2010.

B. K. Ambati, M. Nozaki, N. Singh, A. Takeda, P. D. Jani et al., Corneal avascularity is due to soluble VEGF receptor-1, Nature, vol.443, pp.993-997, 2006.

B. K. Ambati, E. Patterson, P. Jani, C. Jenkins, E. Higgins et al., Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier, Br. J. Ophthalmol, vol.91, pp.505-508, 2007.

X. Fan, A. Rai, N. Kambham, J. F. Sung, N. Singh et al., Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications, J. Clin. Investig, vol.124, pp.4941-4952, 2014.

A. K. Olsson, A. Dimberg, J. Kreuger, and L. Claesson-welsh, VEGF receptor signalling-In control of vascular function, Nat. Rev. Mol. Cell Biol, vol.7, pp.359-371, 2006.

Y. Kumai, H. Ooboshi, S. Ibayashi, E. Ishikawa, H. Sugimori et al., Postischemic gene transfer of soluble FLT-1 protects against brain ischemia with marked attenuation of blood-brain barrier permeability, J. Cereb. Blood Flow Metab, vol.27, pp.1152-1160, 2007.

P. N. Tsao, F. T. Chan, S. C. Wei, W. S. Hsieh, H. C. Chou et al., Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis, Crit. Care Med, vol.35, 1955.

R. J. Levine, S. E. Maynard, C. Qian, K. H. Lim, L. J. England et al., Circulating angiogenic factors and the risk of preeclampsia, N. Engl. J. Med, vol.350, pp.672-683, 2004.

S. E. Maynard, J. Y. Min, J. Merchan, K. H. Lim, J. Li et al., Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia, J. Clin. Investig, vol.111, pp.649-658, 2003.

S. A. Eming, G. Lauer, M. Cole, S. Jurk, H. Christ et al., Increased levels of the soluble variant of the vascular endothelial growth factor receptor VEGFR-1 are associated with a poor prognosis in wound healing, J. Invest. Dermatol, vol.123, pp.799-802, 2004.

R. Malhotra, S. Paskin-flerlage, R. T. Zamanian, P. Zimmerman, J. W. Schmidt et al., Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension, Pulm. Circ, vol.3, pp.369-380, 2013.

T. Wada, S. Jesmin, S. Gando, Y. Yanagida, A. Mizugaki et al., The role of angiogenic factors and their soluble receptors in acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) associated with critical illness, J. Inflamm, vol.10, issue.6, 2013.

C. K. Goldman, R. L. Kendall, G. Cabrera, L. Soroceanu, Y. Heike et al., Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate, Proc. Natl. Acad. Sci, vol.95, pp.8795-8800, 1998.

J. Verrax, F. Defresne, F. Lair, G. Vandermeulen, G. Rath et al., Delivery of soluble VEGF receptor 1 (sFlt1) by gene electrotransfer as a new antiangiogenic cancer therapy, Mol. Pharm, vol.8, pp.701-708, 2011.

K. Takayama, H. Ueno, Y. Nakanishi, T. Sakamoto, K. Inoue et al., Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ, Cancer Res, vol.60, pp.2169-2177, 2000.

S. Shiose, T. Sakamoto, H. Yoshikawa, Y. Hata, Y. Kawano et al., Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma, Investig. Ophthalmol. Vis. Sci, vol.41, pp.2395-2403, 2000.

J. B. Kearney, N. C. Kappas, C. Ellerstrom, F. W. Dipaola, and V. L. Bautch, The VEGF receptor Flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis, Blood, vol.103, pp.4527-4535, 2004.

A. Orecchia, P. M. Lacal, C. Schietroma, V. Morea, G. Zambruno et al., Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the ?5?1 integrin, J. Cell Sci, vol.116, pp.3479-3489, 2003.

T. Miyake, K. Kumasawa, N. Sato, T. Takiuchi, H. Nakamura et al., Soluble VEGF receptor 1 (sFlt1) induces non-apoptotic death in ovarian and colorectal cancer cells, Sci. Rep, 2016.

F. Ruffini, C. M. Failla, A. Orecchia, M. R. Bani, A. S. Dorio et al., Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: Role in tumour progression, Br. J. Dermatol, vol.164, pp.1061-1070, 2011.

A. Thielemann, A. Baszczuk, Z. Kopczynski, P. Kopczynski, and S. Grodecka-gazdecka, Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer, Ann. Agric. Environ. Med, vol.20, pp.293-297, 2013.

K. Lamszus, U. Ulbricht, J. Matschke, M. A. Brockmann, R. Fillbrandt et al., Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin, Cancer Res, vol.9, pp.1399-1405, 2003.

A. Wierzbowska, T. Robak, A. Wrzesien-kus, A. Krawczynska, and E. Lech-maranda, Urbanska-Rys, H. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia, Eur. Cytokine Netw, vol.14, pp.149-153, 2003.

M. Toi, H. Bando, T. Ogawa, M. Muta, C. Hornig et al., Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer, Int. J. Cancer, vol.98, pp.14-18, 2002.

A. L. Harris, P. Reusch, B. Barleon, C. Hang, N. Dobbs et al., Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy, Clin. Cancer Res, 1992.

S. Nagaoka, T. Yoshida, J. Akiyoshi, J. Akiba, T. Hisamoto et al., The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma, Oncol. Rep, vol.23, pp.1647-1654, 2010.

B. Kulapaditharom, V. Boonkitticharoen, and C. Sritara, Plasma vascular endothelial growth factor dysregulation in defining aggressiveness of head and neck squamous cell carcinoma, J. Oncol, vol.687934, 2012.

N. Ilhan, N. Ilhan, and F. Deveci, Functional significance of vascular endothelial growth factor and its receptor (receptor-1) in various lung cancer types, Clin. Biochem, vol.37, pp.840-845, 2004.

Y. T. Chang, M. C. Chang, S. C. Wei, Y. W. Tien, C. Hsu et al., Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer, Pancreas, vol.37, pp.145-150, 2008.

H. Bando, H. A. Weich, M. Brokelmann, S. Horiguchi, N. Funata et al., Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer, Br. J. Cancer, vol.92, pp.553-561, 2005.

S. Aref, M. El-sherbiny, T. Goda, M. Fouda, H. Al-askalany et al., Soluble VEGF/sFlt1 ratio is an independent predictor of aml patient out come, Hematology, vol.10, pp.131-134, 2005.

D. Lambrechts, H. J. Lenz, S. De-haas, P. Carmeliet, and S. J. Scherer, Markers of response for the antiangiogenic agent bevacizumab, J. Clin. Oncol, vol.31, 2013.

S. M. Tolaney, Y. Boucher, D. G. Duda, J. D. Martin, G. Seano et al., Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients, Proc. Natl. Acad. Sci, vol.112, pp.14325-14330, 2015.

A. X. Zhu, R. S. Finn, M. Mulcahy, J. Gurtler, W. Sun et al., A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer, Clin. Cancer Res, vol.19, pp.6614-6623, 2013.

C. G. Willett, D. G. Duda, E. Di-tomaso, Y. Boucher, M. Ancukiewicz et al., Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study, J. Clin. Oncol, vol.27, pp.3020-3026, 2009.

A. Thomas-schoemann, B. Blanchet, P. Boudou-rouquette, J. L. Golmard, G. Noe et al., Soluble VEGFR-1: A new biomarker of sorafenib-related hypertension (i.e., sorafenib-related is the compound adjective?), J. Clin. Pharmacol, vol.55, pp.478-479, 2015.

D. G. Duda, C. G. Willett, M. Ancukiewicz, E. Di-tomaso, M. Shah et al., Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer, Oncologist, vol.15, pp.577-583, 2010.

A. X. Zhu, D. V. Sahani, D. G. Duda, E. Di-tomaso, M. Ancukiewicz et al., Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study, J. Clin. Oncol, vol.27, pp.3027-3035, 2009.

S. Kopetz, P. M. Hoff, J. S. Morris, R. A. Wolff, C. Eng et al., Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance, J. Clin. Oncol, vol.28, pp.453-459, 2010.

J. E. Lee, C. Kim, H. Yang, I. Park, N. Oh et al., Novel glycosylated VEGF decoy receptor fusion protein, VEGF-Grab, efficiently suppresses tumor angiogenesis and progression, Mol. Cancer Ther, vol.14, pp.470-479, 2015.

L. A. Owen, H. Uehara, J. Cahoon, W. Huang, J. Simonis et al., Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization, PLoS ONE, vol.7, 2012.

M. Salton, W. K. Kasprzak, T. Voss, B. A. Shapiro, P. I. Poulikakos et al., Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing, Nat. Commun, vol.6, p.7103, 2015.

M. Salton and T. Misteli, Small molecule modulators of pre-mRNA splicing in cancer therapy, Trends Mol. Med, vol.22, pp.28-37, 2016.

S. C. Lee, H. Dvinge, E. Kim, H. Cho, J. B. Micol et al., Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins, Nat. Med, vol.22, pp.672-678, 2016.